Pharvaris (NASDAQ:PHVS) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Pharvaris (NASDAQ:PHVS - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.81) by $0.04, Zacks reports.

Pharvaris Stock Down 1.6%

PHVS stock traded down $0.55 during midday trading on Friday, hitting $33.28. The company's stock had a trading volume of 92,625 shares, compared to its average volume of 452,374. Pharvaris has a 52-week low of $23.01 and a 52-week high of $43.25. The firm has a market capitalization of $2.18 billion, a P/E ratio of -10.91 and a beta of -2.48. The firm has a 50-day simple moving average of $33.29 and a 200-day simple moving average of $31.29.

Analysts Set New Price Targets

A number of brokerages have recently commented on PHVS. Oppenheimer reaffirmed an "outperform" rating on shares of Pharvaris in a research note on Friday, October 23rd. New Street Research set a $60.00 price objective on Pharvaris in a research note on Friday, August 14th. Royal Bank Of Canada upped their price target on Pharvaris from $52.00 to $62.00 and gave the company an "outperform" rating in a research report on Wednesday, September 9th. HC Wainwright reaffirmed a "buy" rating on shares of Pharvaris in a research note on Tuesday, October 6th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Pharvaris in a research report on Thursday, October 15th. Fourteen investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $59.53.

Insider Buying and Selling at Pharvaris

In other news, Director Viviane Monges sold 11,969 shares of the stock in a transaction on Wednesday, September 23rd. The stock was sold at an average price of $33.05, for a total value of $395,575.45. Following the sale, the director directly owned 5,500 shares in the company, valued at approximately $181,775. This trade represents a 68.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO David Nassif sold 6,000 shares of the stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $36.47, for a total value of $218,820.00. Following the completion of the sale, the chief financial officer directly owned 114,300 shares in the company, valued at $4,168,521. This represents a 4.99% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 510,810 shares of company stock valued at $18,563,973. Insiders own 11.84% of the company's stock.

Pharvaris Company Profile

Pharvaris N.V. is a clinical-stage biopharmaceutical company focused on developing oral treatments for hereditary angioedema (HAE) and other conditions involving bradykinin-mediated swelling. The company was founded in 2015 and is based in Leiden, the Netherlands. Its lead candidate, deucrictibant, is an oral small-molecule antagonist of the bradykinin B2 receptor. Pharvaris is studying the candidate in different formulations for both on-demand treatment of HAE attacks and prevention of attacks.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.